Izamby

Denosumab, the active ingredient in Izamby, is a RANKL inhibitor presented as a subcutaneous injection for subcutaneous use. It reduces bone resorption in patients with osteoporosis, bone loss associated with cancer treatment, and helps prevent skeletal‑related events in patients with bone metastases.

GNH USA supplies Izamby as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Izamby (denosumab) targets the RANK/RANKL pathway in conditions characterized by increased bone resorption.

- Postmenopausal osteoporosis: reduces risk of vertebral, hip and non‑vertebral fractures. - Bone loss in men receiving androgen deprivation therapy for prostate cancer: maintains bone mineral density. - Bone metastases from solid tumours: delays skeletal‑related events such as pathological fractures. - Giant cell tumour of bone (recurrent or unresectable): inhibits tumour progression.

Common Side Effects: - Injection site reactions: pain, redness or swelling at the injection site. - Hypocalcaemia: low blood calcium levels, often asymptomatic. - Musculoskeletal pain: joint or muscle discomfort. - Upper respiratory tract infection: mild cold‑like symptoms. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Osteonecrosis of the jaw: exposed bone in the oral cavity. - Atypical femur fracture: unusual break in the thigh bone. - Severe hypocalcaemia: symptomatic low calcium requiring medical intervention. - Anaphylaxis: severe allergic reaction with breathing difficulty. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Serious infections: opportunistic infections due to immune modulation.

Before initiating therapy, consider the following precautions: - Calcium and vitamin D supplementation: ensure adequate intake to reduce hypocalcaemia risk. - Renal function monitoring: assess calcium levels in patients with impaired kidney function. - Dental examination: obtain a dental assessment before starting therapy to lower risk of osteonecrosis of the jaw. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks; limited data are available. - Concomitant medications: review for drugs that affect calcium metabolism. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Denosumab may interact with several medicines. Monitor the following:

Major Interactions (Avoid): - Bisphosphonates: concurrent use can increase the risk of severe hypocalcaemia. - Other RANKL inhibitors: additive effect on bone turnover, not recommended.

Moderate Interactions (Monitor Closely): - Loop diuretics: may exacerbate calcium loss. - Anticonvulsants (e.g., phenytoin, phenobarbital): can reduce vitamin D levels, affecting calcium balance. - Corticosteroids: may worsen bone loss when combined. - Hormone therapy (estrogen, testosterone): may influence overall bone metabolism.